![[Video] The Weekly Break Out Ep. 19: Army aviation’s shakeup and the F-35’s future](https://breakingdefense.com/wp-content/uploads/sites/3/2025/05/EP-19-THUMB-play-button.jpg?#)
Biotech incubated by TCG Labs inks $210M deal for EpimAb's T-cell engager
TCG Labs Soleil’s Juri Biosciences is offering EpimAb Biotherapeutics up to $210 million biobucks for exclusive licensing rights to the China biotech’s T-cell engager designed to treat metastatic prostate cancer.
TCG Labs Soleil’s Juri Biosciences is offering EpimAb Biotherapeutics up to $210 million biobucks for exclusive licensing rights to the China biotech’s T-cell engager designed to treat metastatic prostate cancer.
